{
    "clinical_study": {
        "@rank": "97500", 
        "arm_group": [
            {
                "arm_group_label": "Healthy volunteers group 1", 
                "arm_group_type": "Experimental", 
                "description": "Healthy volunteers with normal renal function"
            }, 
            {
                "arm_group_label": "Renal function group 2", 
                "arm_group_type": "Experimental", 
                "description": "Patients with mild renal impairment"
            }, 
            {
                "arm_group_label": "Renal function group 3", 
                "arm_group_type": "Experimental", 
                "description": "Patients with moderate renal impairment"
            }, 
            {
                "arm_group_label": "Renal function group 4", 
                "arm_group_type": "Experimental", 
                "description": "Patients with servere renal impairment"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the trial is to investigate the effect of different degrees of renal\n      impairment on the pharmacokinetics and safety of the combination of BI 207127 and\n      faldaprevir after 3 days of dosing (BI 207127 bid, faldaprevir qd) and a single dose of BI\n      207127 and faldaprevir on day 4."
        }, 
        "brief_title": "Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Insufficiency", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy volunteers (males and females) or patients with impaired renal function\n             (estimated glomerular filtration rate (eGFR) between 89 and 15) in relatively good\n             health as determined by past medical history, physical examination, vital signs, ECG\n             and laboratory assessments (aside from abnormalities specific for renal impairment)\n\n          -  Age from 18 to 79 years\n\n          -  Subjects must be able to understand and comply with study requirements\n\n        Exclusion criteria:\n\n          -  Any relevant deviation from healthy conditions for healthy volunteers\n\n          -  Subjects with significant diseases other than renal impairment will be excluded. A\n             significant disease is defined as a disease which in the opinion of the investigator:\n\n               -  put the patient at risk because of participation in the study\n\n               -  may influence the results of the study\n\n               -  may influence the patients ability to participate in the study\n\n               -  is not in a stable condition\n\n          -  Diabetic or hypertensive patients can be entered in this trial if the disease is not\n             significant according to these criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957657", 
            "org_study_id": "1241.32", 
            "secondary_id": "2013-001075-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Renal function group 2", 
                "description": "oral administration", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Renal function group 2", 
                "description": "oral administration", 
                "intervention_name": "faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Renal function group 4", 
                "description": "oral administration", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Healthy volunteers group 1", 
                "description": "oral administration", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Renal function group 3", 
                "description": "oral administration", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Renal function group 3", 
                "description": "oral administration", 
                "intervention_name": "faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Healthy volunteers group 1", 
                "description": "oral administration", 
                "intervention_name": "faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Renal function group 4", 
                "description": "oral administration", 
                "intervention_name": "faldaprevir", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kiel", 
                    "country": "Germany"
                }, 
                "name": "1241.32.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Single Center, Open-label, Parallel-group, Phase I Trial", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of BI 207127 in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of BI 207127 in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number (%) of subjects with drug-related adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 18 days"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites (CD 6168) in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites (BI 208333) in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites (CD 6168 acylglucuronide) in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites faldaprevir in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of BI 207127 metabolites (CD 6168) in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of BI 207127 metabolites (BI 208333) in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of BI 207127 metabolites (CD 6168 acylglucuronide) in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of BI 207127 metabolites faldaprevir in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 10 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}